Avidity Biosciences (RNA) Q2 2025 earnings summary

Executive summary

• Focused on developing Antibody Oligonucleotide Conjugates (AOCs) for rare neuromuscular diseases, with three lead programs in registrational trials for DMD, DM1, and FSHD, all with FDA Orphan and Fast Track designations.

• Achieved key clinical milestones: positive Phase 1/2 data for DMD44 and FSHD, completion of Phase 3 enrollment for DM1, and FDA alignment for FSHD and DMD44 approval pathways.

• On track for three BLA submissions within a 12-month period, with the first for DMD44 planned by year-end 2025.

• Strong cash position and runway to mid-2027, enabling readiness for global commercial launch, with first potential U.S. launch in 2026.

• No product sales to date; revenue derived from collaboration agreements with BMS and Eli Lilly.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1.2 billion as of June 30, 2025.

• Net loss was $157.3 million for Q2 2025 and $273.1 million for the first half of 2025, compared to $70.8 million and $139.6 million for the same periods in 2024.

• Research and development expenses rose to $138.1 million in Q2 2025, up from $63.9 million in Q2 2024, driven by clinical trial progression and manufacturing costs.

• General and administrative expenses increased to $36.9 million in Q2 2025, up from $20.7 million in Q2 2024, mainly due to higher personnel and commercial infrastructure costs.

• Net proceeds of $185.5 million received post-quarter from at-the-market stock offering.

Outlook and guidance

• Cash and equivalents, including recent offering proceeds, expected to fund operations through mid-2027.

• Anticipates first BLA submission for DMD44 by year-end 2025 and topline data from key trials in 2025–2026.

• First potential commercial launch in the U.S. anticipated in 2026, with three BLA submissions planned over a 12-month period.

• Topline and functional data from EXPLORE44-OLET trial expected in Q4 2025; HARBOR study topline data anticipated in Q2 2026.

• Expects expenses and operating losses to increase as clinical and commercial activities expand.